Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
CC transcript
Employment agrmnt
Coll. bargaining agrmnt
Director departure
NOVELION THERAPEUTICS INC. (NVLNF) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2019 GN Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters
09/25/2019 GN Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers
09/11/2019 GN Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders
08/30/2019 GN Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
08/21/2019 GN Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
08/12/2019 GN Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
07/16/2019 GN Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
07/05/2019 GN Novelion Therapeutics Receives Delisting Notifications
05/20/2019 GN Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
05/07/2019 GN Novelion Therapeutics Reports First Quarter 2019 Financial Results
03/31/2019 GN Novelion Therapeutics Observes World Lipodystrophy Day
03/14/2019 GN Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
02/06/2019 GN Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
11/20/2018 GN Novelion Therapeutics Announces Leadership Change
11/09/2018 GN Novelion Therapeutics Reports Third Quarter 2018 Financial Results
09/24/2018 GN Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
08/23/2018 GN Novelion Therapeutics Announces Next Phase of Operational Improvements
08/07/2018 GN Novelion Therapeutics Reports Second Quarter 2018 Financial Results
07/31/2018 GN Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
07/03/2018 GN Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
06/01/2018 GN MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
05/10/2018 GN Novelion Therapeutics Reports First Quarter 2018 Financial Results
03/31/2018 GN Novelion Therapeutics Supports World Lipodystrophy Day
03/15/2018 GN Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
03/15/2018 GN Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
01/30/2018 GN Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
01/24/2018 GN Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
09/24/2012 GN QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
05/03/2012 GN QLT Announces First Quarter 2012 Results
04/19/2012 GN Media Advisory: QLT to Report First Quarter Financial Results on May 3, 2012
03/19/2012 GN QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
03/08/2012 GN Media Advisory: QLT to Present at ROTH Capital Partners Annual Growth Stock Conference
02/23/2012 GN QLT Announces Fourth Quarter and Year End 2011 Results
02/16/2012 GN Media Advisory: QLT to Report 2011 Fourth Quarter and Year End Financial Results on February 23, 2012
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy